Provided are small molecule inhibitors of ubiquitin specific protease 1 (USP1) activity and methods for their use in treating and characterizing cancers. The small molecule USP1 inhibitors of the invention are particularly useful in the treatment of cancers that are resistant to DNA cross-linking agents.

Compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. Compositions that include one or more such compounds. Articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one such compound.

Compounds that have ultraviolet light absorbing properties, and which can also have mesogenic properties. Compositions that include one or more such compounds. Articles of manufacture that include one or more such compounds, such as optical elements that include an optical substrate and a layer that includes at least one such compound.

A compound of Chemical Formula 1 or 2 and an organic light emitting device including the same are provided. The compound, when used as a material for an organic material layer of an organic light emitting device, provides improved efficiency, low driving voltage, and enhanced lifespan of the organic light emitting device.

##STR00001##

A compound of Chemical Formula 1 or 2 and an organic light emitting device including the same are provided. The compound, when used as a material for an organic material layer of an organic light emitting device, provides improved efficiency, low driving voltage, and enhanced lifespan of the organic light emitting device.

##STR00001##

Provided are small molecule inhibitors of ubiquitin specific protease 2, 8 and 12 (USP2 and USP8 and USP12) activity and methods for their use in treating cancers. The small molecule inhibitors of the invention are particularly useful in the treatment of non-small cell lung cancers that are resistant to tyrosine kinase inhibitors and in the treatment of prostate cancer that is resistant to AR inhibitor therapy. ##STR00001##

Provided are small molecule inhibitors of ubiquitin specific protease 2, 8 and 12 (USP2 and USP8 and USP12) activity and methods for their use in treating cancers. The small molecule inhibitors of the invention are particularly useful in the treatment of non-small cell lung cancers that are resistant to tyrosine kinase inhibitors and in the treatment of prostate cancer that is resistant to AR inhibitor therapy. ##STR00001##

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

The present disclosure relates to organic electroluminescent devices. The organic electroluminescent device according to the present disclosure exhibits improved lifespan characteristics and progressive driving voltage by including at least one deuterated compound(s).